Impaired c-met receptor degradation mediated by MET exon 14 mutations in non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 34, Issue 8, 2016, Pages 879-881

  Awad, Mark M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SCATTER FACTOR RECEPTOR; MET PROTEIN, HUMAN;

CANCER PROGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; EXON; GENE DELETION; GENE DOSAGE; HUMAN; INTRON; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SHORT SURVEY; GENE AMPLIFICATION; GENETICS; LUNG TUMOR; METABOLISM; MUTATION;

CARCINOMA, NON-SMALL-CELL LUNG; EXONS; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MUTATION; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84961194761     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.2777     Document Type: Short Survey

References (49)

1. World Health Organization: Cancer fact sheet, 2015. http://www.who.int/mediacentre/factsheets/fs297/en/
2. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
3. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
4. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311, 2004
5. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703, 2010
6. Shaw AT, Kim DW, Mehra R, et al: Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370:1189-1197, 2014
7. Seto T, Kiura K, Nishio M, et al: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1-2 study. Lancet Oncol 14:590-598, 2013
8. Bergethon K, Shaw AT, Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870, 2012
9. Shaw AT, Ou SH, Bang YJ, et al: Crizotinib in ROS1-rearranged non-small-cell lung cancer. NEngl J Med 371:1963-1971, 2014
10. Planchard D, Groen HJM, Kim TM, et al: Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated(mut) metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 33, 2015 (suppl; abstr 8006)
11. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
12. Kris MG, Johnson BE, Berry LD, et al: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311: 1998-2006, 2014
13. Brahmer J, Reckamp KL, Baas P, et al: Nivo-lumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135, 2015
14. Paz-Ares L, Horn L, Borghaei H, et al: Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 33, 2015 (suppl; abstr LBA109)
15. Koeppen H, Yu W, Zha J, et al: Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib 6 onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res 20: 4488-4498, 2014
16. Cappuzzo F, Marchetti A, Skokan M, et al: Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27:1667-1674, 2009
17. Dimou A, Non L, Chae YK, et al: MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC): A systematic review and meta-analysis. PLoS One 9: e107677, 2014
18. Sacco JJ, Clague MJ: Dysregulation of the Met pathway in non-small cell lung cancer: Implications for drug targeting and resistance. Transl Lung Cancer Res 4:242-252, 2015
19. Stransky N, Cerami E, Schalm S, et al: The landscape of kinase fusions in cancer. Nat Commun 5:4846, 2014
20. Spigel DR, Edelman MJ, O'Byrne K, et al: Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 32:5s, 2014 (suppl; abstr 8000)
21. Onozato R, Kosaka T, Kuwano H, et al: Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 4: 5-11, 2009
22. Ou SH, Kwak EL, Siwak-Tapp C, et al: Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6:942-946, 2011
23. Camidge DR, Ou S-HI, Shapiro G, et al: Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 32:5s, 2014 (suppl; abstr 8001)
24. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007
25. Turke AB, Zejnullahu K, Wu YL, et al: Preex-istence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17:77-88, 2010
26. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26, 2011
27. Yu HA, Arcila ME, Rekhtman N, et al: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19:2240-2247, 2013
28. Gherardi E, Birchmeier W, Birchmeier C, et al: Targeting MET in cancer: Rationale and progress. Nat Rev Cancer 12:89-103, 2012
29. Peschard P, Fournier TM, Lamorte L, et al: Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8:995-1004, 2001
30. Abella JV, Peschard P, Naujokas MA, et al: Met/hepatocyte growth factor receptor ubiquiti-nation suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 25:9632-9645, 2005
31. Frampton GM, Ali SM, Rosenzweig M, et al: Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5:850-859, 2015
32. Liu X, Jia Y, Stoopler MB, et al: Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol 34:794-802, 2016
33. Peschard P, Park M: From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 26:1276-1285, 2007
34. Levkowitz G, Waterman H, Zamir E, et al: c-Cbl/Sli-1 regulates endocytic sorting and ubiquitina-tion of the epidermal growth factor receptor. Genes Dev 12:3663-3674, 1998
35. Levkowitz G, Oved S, Klapper LN, et al: c-Cbl is a suppressor of the neu oncogene. J Biol Chem 275: 35532-35539, 2000
36. Ma PC, Jagadeeswaran R, Jagadeesh S, et al: Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65:1479-1488, 2005
37. Kong-Beltran M, Seshagiri S, Zha J, et al: Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66:283-289, 2006
38. Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adeno-carcinoma. Nature 511:543-550, 2014
39. Erratum: Nature 514:262, 2014
40. Paik PK, Drilon A, Fan PD, et al: Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 5:842-849, 2015
41. Yendamuri S, Caty L, Pine M, et al: Outcomes of sarcomatoid carcinoma of the lung: A Surveillance, Epidemiology, and End Results Database analysis. Surgery 152:397-402, 2012
42. Vieira T, Girard N, Ung M, et al: Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol 8: 1574-1577, 2013
43. Tan YH, Krishnaswamy S, Nandi S, et al: CBL is frequently altered in lung cancers: Its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One 5:e8972, 2010
44. Erratum: PLoS One 6:doi:10.1371/annotation/940edb14-522e-4f38-b6c4-7557e9a13d15, 2011
45. Sanada M, Suzuki T, Shih LY, et al: Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460:904-908, 2009
46. Makishima H, Cazzolli H, Szpurka H, et al: Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 27:6109-6116, 2009
47. Jenkins RW, Oxnard GR, Elkin S, et al: Response to crizotinib in a patient with lung adeno-carcinoma harboring a MET splice site mutation. Clin Lung Cancer 16:e101-e104, 2015
48. Waqar SN, Morgensztern D, Sehn J: MET mutation associated with responsiveness to crizoti-nib. J Thorac Oncol 10:e29-e31, 2015
49. Mendenhall MA, Goldman JW: MET-mutated NSCLC with major response to crizotinib. J Thorac Oncol 10:e33-e34, 2015